Editorial and Evidence Review Policy
How sources, study designs, numerical claims, commercial conflicts, AI assistance, corrections and publication thresholds are handled.
Last updated: September 2026
Scope and Commercial Interest
This website publishes product-family dossiers, study reviews, comparisons, regulatory context and analytical-quality guides for research-material procurement. The website also accepts commercial enquiries for research materials; that relationship is a potential conflict of interest and is disclosed on evidence-led pages.
Published content is educational and procurement-oriented. It is not medical advice, a clinical recommendation, an administration guide or independent peer review.
Source Priority
- Primary peer-reviewed research is preferred for study methods, populations, endpoints and numerical results.
- Regulator labels, safety communications, assessment documents and trial registries are preferred for approval, safety and development status.
- Authoritative chemical databases may support identity context but do not verify a supplied lot.
- Sponsor announcements are labeled as sponsor-reported and are not treated as peer-reviewed outcomes.
- Secondary reviews provide context and do not replace the underlying primary record when one is available.
Evidence Extraction and Boundaries
- Editors record the study model or population, design, intervention, comparator, duration, endpoints and reported numerical result where relevant.
- Human, animal, in-vitro, analytical, registry and sponsor evidence are kept visibly distinct.
- An approved finished medicine is not treated as evidence that a catalog research material is clinically interchangeable.
- HPLC area purity, intact mass, assay, water, counterion and residual-solvent measurements are not treated as equivalent quantities.
- Where identity, composition or lot documentation is not independently available, the page states that limitation instead of inferring a result.
Review, Updates and Corrections
Pages display a last source-check date or editorial status where the workflow has been completed. Regulatory and development-status pages should be rechecked when a new label, regulator action, trial record or primary publication appears.
Corrections are made when a cited source no longer supports the wording, a numerical extraction is wrong, a material identity is ambiguous or a page overstates the applicable evidence. Substantive changes should update the page modification date.
AI-Assisted Production
Automation or generative tools may assist with drafting, formatting, image concepts, deduplication and source organization. They are not accepted as evidence. Citations, numerical claims, study models, regulatory status and evidence boundaries must be checked against the linked source record before a page is marked reviewed.
Publication Threshold
- Each indexable article must answer a distinct research question and add analysis beyond a product page summary.
- Pages without adequate source support remain on editorial hold, are merged into a stronger page or are excluded from search indexing.
- Customer or project case studies are published only with authorization and verifiable methods and outcomes; no synthetic testimonials or cases are created for search traffic.
